Zapolin's discussion of the potential of psychedelics in mental health, addiction, and peak performance highlights the growing interest in this field. The mention of Psycheceutical's neurodirect ketamine entering clinical trials in Australia indicates progress in the company's product development, which could positively impact the stock price in the short term.